Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
$25.63
+1.5%
$25.85
$16.54
$28.67
$380.04M0.7478,469 shs85,864 shs
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
$31.09
-7.2%
$29.03
$23.10
$48.47
$739.51M1.16182,826 shs151,608 shs
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$76.13
+0.2%
$66.67
$44.27
$76.24
$1.71B0.88122,385 shs86,101 shs
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$4.86
-3.6%
$6.03
$4.38
$8.45
$371.84M0.23872,032 shs1.04 million shs
Surmodics, Inc. stock logo
SRDX
Surmodics
$32.16
-0.5%
$28.58
$16.79
$39.41
$458.60M1.0462,699 shs30,336 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-11.28%-8.45%-2.43%+5.12%0.00%
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
+0.93%+5.28%+10.16%+16.89%-26.97%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
+1.33%+13.82%+13.50%+23.62%+16.21%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
-4.99%-7.94%-14.92%-29.83%-28.44%
Surmodics, Inc. stock logo
SRDX
Surmodics
+2.31%-6.45%+16.47%-1.22%+58.63%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
3.3965 of 5 stars
2.31.00.03.62.51.71.9
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
4.119 of 5 stars
3.41.00.03.92.54.20.6
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.279 of 5 stars
1.42.03.30.01.93.31.9
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
4.1497 of 5 stars
3.22.00.04.22.01.71.9
Surmodics, Inc. stock logo
SRDX
Surmodics
4.1197 of 5 stars
3.52.00.03.41.71.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
2.50
Moderate Buy$29.5015.10% Upside
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
2.75
Moderate Buy$45.5046.35% Upside
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.71
Moderate Buy$73.83-3.02% Downside
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
2.33
Hold$6.3831.17% Upside
Surmodics, Inc. stock logo
SRDX
Surmodics
3.00
Buy$57.0077.24% Upside

Current Analyst Ratings

Latest ANIK, SRDX, LMAT, KIDS, and OSUR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2024
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$37.00 ➝ $37.00
5/8/2024
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$35.00 ➝ $38.00
5/7/2024
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$37.00 ➝ $42.00
5/7/2024
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$50.00
5/3/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$72.00 ➝ $77.00
5/3/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$69.00 ➝ $79.00
5/2/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$71.00 ➝ $71.00
5/1/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$47.00 ➝ $43.00
4/26/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$59.00 ➝ $75.00
4/10/2024
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$37.00
4/10/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$47.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
$166.66M2.28$4.57 per share5.61$14.50 per share1.77
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
$161.83M4.57N/AN/A$16.14 per share1.93
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$199.89M8.55$1.83 per share41.56$13.38 per share5.69
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$405.47M0.92$1.19 per share4.09$5.86 per share0.83
Surmodics, Inc. stock logo
SRDX
Surmodics
$132.58M3.46$0.78 per share41.43$8.48 per share3.79

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-$82.67M-$5.65N/A18.992.46-49.60%-2.10%-1.71%8/13/2024 (Estimated)
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
-$20.97M-$0.96N/AN/AN/A-14.10%-5.03%-4.37%7/29/2024 (Estimated)
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$30.10M$1.5150.4241.152.9916.99%11.57%10.02%8/6/2024 (Estimated)
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$53.65M$0.306.75N/AN/A13.23%14.50%12.69%8/1/2024 (Estimated)
Surmodics, Inc. stock logo
SRDX
Surmodics
-$1.54M$0.9533.85N/AN/A9.44%13.30%8.63%8/7/2024 (Estimated)

Latest ANIK, SRDX, LMAT, KIDS, and OSUR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024Q1 2024
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$0.04$0.04N/A$0.05$52.27 million$54.10 million    
5/2/2024Q1 2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.39$0.44+$0.05$0.44$51.50 million$53.48 million    
5/1/2024Q2 2024
Surmodics, Inc. stock logo
SRDX
Surmodics
-$0.36$0.07+$0.43$0.12$28.79 million$31.96 million    
3/13/2024Q4 2023
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-$0.15$0.05+$0.20$4.40$41.51 million$42.97 million
3/6/2024Q4 2023
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
-$0.28-$0.23+$0.05-$0.17$37.59 million$37.61 million
2/27/2024Q4 2023
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.36$0.38+$0.02$0.38$49.01 million$48.90 million    
2/27/2024Q4 2023
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$0.13$0.22+$0.09$0.17$74.13 million$75.88 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
N/AN/AN/AN/AN/A
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
N/AN/AN/AN/AN/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.640.84%+13.80%42.38%13 Years
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/AN/AN/AN/AN/A
Surmodics, Inc. stock logo
SRDX
Surmodics
N/AN/AN/AN/AN/A

Latest ANIK, SRDX, LMAT, KIDS, and OSUR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Quarterly$0.160.86%5/15/20245/16/20245/30/2024
2/21/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Quarterly$0.160.9%3/13/20243/14/20243/28/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
N/A
5.26
3.76
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
0.03
5.44
2.90
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
N/A
7.57
5.31
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/A
9.77
8.57
Surmodics, Inc. stock logo
SRDX
Surmodics
0.24
4.39
3.59

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
91.53%
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
69.05%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
84.64%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
93.50%
Surmodics, Inc. stock logo
SRDX
Surmodics
96.63%

Insider Ownership

CompanyInsider Ownership
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
5.85%
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
31.80%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
10.79%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
3.40%
Surmodics, Inc. stock logo
SRDX
Surmodics
8.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
35714.83 million13.96 millionOptionable
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
24723.79 million16.22 millionOptionable
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
61422.45 million20.02 millionOptionable
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
63876.51 million73.91 millionOptionable
Surmodics, Inc. stock logo
SRDX
Surmodics
37614.26 million12.99 millionOptionable

ANIK, SRDX, LMAT, KIDS, and OSUR Headlines

SourceHeadline
Surmodics (NASDAQ:SRDX) Receives Outperform Rating from Barrington ResearchSurmodics (NASDAQ:SRDX) Receives Outperform Rating from Barrington Research
americanbankingnews.com - May 6 at 5:38 AM
Q3 2025 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Reduced by AnalystQ3 2025 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Reduced by Analyst
americanbankingnews.com - May 6 at 3:50 AM
Surmodics, Inc. Just Beat Earnings Expectations: Heres What Analysts Think Will Happen NextSurmodics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
finance.yahoo.com - May 4 at 11:04 AM
Surmodics (SRDX) Q2 Earnings Top Estimates, 24 View UpSurmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up
zacks.com - May 3 at 2:16 PM
Surmodics (NASDAQ:SRDX) Price Target Cut to $43.00Surmodics (NASDAQ:SRDX) Price Target Cut to $43.00
americanbankingnews.com - May 3 at 5:18 AM
Surmodics (NASDAQ:SRDX) Rating Reiterated by Barrington ResearchSurmodics (NASDAQ:SRDX) Rating Reiterated by Barrington Research
marketbeat.com - May 2 at 3:39 PM
Surmodics (NASDAQ:SRDX) Releases  Earnings Results, Beats Expectations By $0.43 EPSSurmodics (NASDAQ:SRDX) Releases Earnings Results, Beats Expectations By $0.43 EPS
marketbeat.com - May 2 at 2:16 PM
Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and SurModics (SRDX)Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and SurModics (SRDX)
markets.businessinsider.com - May 2 at 12:58 PM
Surmodics Inc (SRDX) Q2 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...Surmodics Inc (SRDX) Q2 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...
finance.yahoo.com - May 2 at 7:36 AM
Surmodics, Inc. (SRDX) stock price, news, quote & history – Yahoo FinanceSurmodics, Inc. (SRDX) stock price, news, quote & history – Yahoo Finance
uk.finance.yahoo.com - May 1 at 9:25 PM
SurModics Outperforms with Raised Guidance and Strong Product Momentum: Buy Rating ReaffirmedSurModics Outperforms with Raised Guidance and Strong Product Momentum: Buy Rating Reaffirmed
markets.businessinsider.com - May 1 at 9:25 PM
Surmodics (NASDAQ:SRDX) PT Lowered to $43.00Surmodics (NASDAQ:SRDX) PT Lowered to $43.00
marketbeat.com - May 1 at 3:06 PM
SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q2 2024SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q2 2024
investorplace.com - May 1 at 1:02 PM
Surmodics (NASDAQ:SRDX) Issues FY 2024 Earnings GuidanceSurmodics (NASDAQ:SRDX) Issues FY 2024 Earnings Guidance
marketbeat.com - May 1 at 10:57 AM
SurModics (SRDX) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesSurModics (SRDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com - May 1 at 10:35 AM
SurModics (SRDX) Q2 Earnings and Revenues Top EstimatesSurModics (SRDX) Q2 Earnings and Revenues Top Estimates
zacks.com - May 1 at 9:31 AM
SurModics: Fiscal Q2 Earnings SnapshotSurModics: Fiscal Q2 Earnings Snapshot
timesunion.com - May 1 at 9:28 AM
Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial GuidanceSurmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
businesswire.com - May 1 at 7:00 AM
SurModics earnings: heres what Wall Street expectsSurModics earnings: here's what Wall Street expects
markets.businessinsider.com - April 30 at 1:24 PM
Can the 4 Medical Device Stocks Hit Targets This Earnings Season?Can the 4 Medical Device Stocks Hit Targets This Earnings Season?
finance.yahoo.com - April 30 at 1:24 PM
Surmodics (SRDX) Set to Announce Quarterly Earnings on WednesdaySurmodics (SRDX) Set to Announce Quarterly Earnings on Wednesday
marketbeat.com - April 24 at 6:45 AM
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
businesswire.com - April 19 at 7:00 AM
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should KnowWill SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
finance.yahoo.com - April 17 at 2:18 PM
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should KnowWill SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
zacks.com - April 17 at 11:06 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Anika Therapeutics logo

Anika Therapeutics

NASDAQ:ANIK
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
OrthoPediatrics logo

OrthoPediatrics

NASDAQ:KIDS
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
LeMaitre Vascular logo

LeMaitre Vascular

NASDAQ:LMAT
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
OraSure Technologies logo

OraSure Technologies

NASDAQ:OSUR
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
Surmodics logo

Surmodics

NASDAQ:SRDX
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.